LAV Biosciences Fund V L.P. 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:21 pm Unchanged | 2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | LAV Biosciences Fund V L.P. | 2,901,566 4.700% | 0 (Unchanged) | Filing |
| 2023-02-06 2:45 pm Sale | 2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | LAV Biosciences Fund V L.P. | 2,901,566 6.100% | -63,304 (-2.14%) | Filing |
| 2022-12-29 2:57 pm Sale | 2022-12-27 | 13G | Terns Pharmaceuticals, Inc. TERN | LAV Biosciences Fund V L.P. | 2,964,870 6.180% | -1,816,696 (-37.99%) | Filing |
| 2022-02-09 12:29 pm Purchase | 2021-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | LAV Biosciences Fund V L.P. | 4,781,566 18.900% | 4,781,566 (New Position) | Filing |